<DOC>
	<DOCNO>NCT00452218</DOCNO>
	<brief_summary>The purpose study assess safety tolerability sorafenib patient PAH already exist therapy prostacyclin [ epoprostenol ( Flolan ) ] , treprostinil ( Remodulin ) , iloprost alone , without sildenafil ( Viagra/Revatio ) .</brief_summary>
	<brief_title>Sorafenib Study : Dosing Patients With Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description>Pulmonary arterial hypertension ( PAH ) angioproliferative vasculopathy result abnormal endothelial smooth muscle cell interaction . Idiopathic familial PAH ( formerly know primary pulmonary hypertension ) occur often woman men , median survival 2.8 year untreated mean age diagnosis 35 year . The key feature vasculopathy cause progressive narrowing pulmonary artery branch , result right heart failure death . Proliferating endothelial cell obliterate medium-sized precapillary artery , thereby form characteristic `` plexiform '' lesion . When combined expansion vascular smooth muscle cell adventitial cell pulmonary artery , observation evoke comparison cancer pathobiology . Currently , FDA-approved therapy PAH prostacyclins ( epoprostenol , treprostinil , iloprost ) , endothelin receptor blocker ( bosentan ) phosphodiesterase inhibitor ( sildenafil ) produce functional improvement ( 6 minute walk distance- 6MW ) minimal change hemodynamic measurement cardiac catheterization . Only epoprostenol provide survival benefit 5-year survival , remain 50 % without demonstrable reversal vasculopathy . Clearly critical need novel target therapy PAH . In protocol , principal investigator ( PI ) leverage large PAH referral practice establish clinical database ass potential utility kinase inhibitor new class agent protease-activated receptor ( PAR ) . These drug inhibit process important pathological blood vessel branch growth focus internationally renowned University Chicago Phase I/II trial unit oncology lead Dr. Mark Ratain ( Co-Investigator ) . The University Chicago major role drug development recently ( 12/05 ) FDA-approved drug , sorafenib , advance renal carcinoma . Sorafenib inhibit Raf-1 kinase , regulator endothelial apoptosis , inhibits angiogenesis growth factor receptor VEGFR-2 , PDGFR-B , VEGFR-3 .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Inclusion criterion : Age &gt; 18 year PAH define IPAH , FPAH , PAH associate collagen vascular disease Baseline 6MW &gt; 150 meter PAH define hemodynamics diagnosis right heart catheterization define : mean PAP &gt; 25 mmHg normal PCWP &lt; 15 mm Hg rest PVR &gt; 3 Wood unit Receiving conventional therapy clinically indicate ( oxygen , diuretic , aldosterone antagonist , calcium channel blocker , digoxin ) dose unchanged precede 30 day prior enrollment . This exclude anticoagulant ( warfarin ) patient 's dose may stable patient cardiac catheterization baseline within 30 day enrollment warfarin held . The dose warfarin need stable 7 day therapeutic INR = 2.0 If intravenous/subcutaneous prostacyclin stable dose &gt; 30 day If subject sildenafil , must stable dose &gt; 30 day Must right heart catheterization prostacyclin + sildenafil within precede 30 day . Subjects must stable dose medication within 30 day prior cardiac catheterization therefore dosage change medication catheterization baseline Must pulmonary function test ( PFT ) within 90 day prior enrollment : TLC , FEV1 , FVC , DLCO Women childbearing year must use adequate contraception ( hormonal barrier method birth control ) prior enrollment . Subjects need negative serum urine pregnancy test . Ability understand willingness sign write informed consent document Exclusion Criteria PAH associate etiology : HIV , portopulmonary disease , congenital heart disease Subjects pulmonary hypertension due thromboembolism , significant interstitial lung disease , chronic obstructive pulmonary disease , congestive heart failure , valvular heart disease Subjects ( World Health Organization ( WHO ) functional Class IV ( 19 ) Subjects scleroderma total lung capacity ( TLC ) &lt; 60 % predict within 30 day screen Subjects significant obstructive lung disease FEV1/FVC &lt; 80 % predicted Subjects hypotension define systolic arterial pressure &lt; 90 mmHg baseline Subjects hypertension define systolic arterial pressure &gt; 140 mmHg baseline diastolic arterial pressure &gt; 90 mmHg Subjects impair renal function define creatinine clearance &lt; 30 ml/min define CockcroftGault formula : Male : creatinine clearance ( ml/min ) = ( 140age ) x ( body weight kg ) / ( 72x serum creatinine mg/dl ) ; Female : creatinine clearance ( ml/min ) = 0.85 ( 140age ) x ( body weight kg ) / ( 72x serum creatinine mg/dl ) Subjects liver function test ( transaminase ( AST/ALT ) , total bilirubin , alkaline phosphatase ) &gt; 2X normal value Subjects acutely decompensated heart failure hospitalization within previous 30 day prior screen Subjects may receive investigational agent Subjects endothelin receptor antagonist ( bosentan , sitaxsentan , ambrisentan ) chronic arginine supplementation Subjects leave ventricular ejection fraction &lt; 45 % leave ventricular shorten fraction &lt; 0.2 Subjects acute myocardial infarction within 90 day prior screen Subjects limitation performance exercise measure ( 6MW ) due condition PH associate dyspnea/fatigue Subjects take nitrate medical problem Subjects take phosphodiesterase inhibitor ( formulation ) erectile dysfunction Subjects recent ( &lt; 180 day ) history pulmonary embolism verify ventilation/perfusion scan , angiogram , spiral CT scan Pregnant lactate woman Subjects history current drug abuse include alcohol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>PAH</keyword>
</DOC>